• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
City of Hope National Medical Center - Developmental Therapeutics Review - Q4 2010 Product Image

City of Hope National Medical Center - Developmental Therapeutics Review - Q4 2010

  • ID: 1464045
  • December 2010
  • 104 pages
  • Global Markets Direct

City of Hope National Medical Center – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “City of Hope National Medical Center – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by City of Hope National Medical Center.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products READ MORE >



List of Tables
List of Figures
City of Hope National Medical Center Snapshot
fKey Information
Key Facts
City of Hope National Medical Center – Research and Development Overview
Key Therapeutic Areas
City of Hope National Medical Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
City of Hope National Medical Center – Pipeline Products Glance
City of Hope National Medical Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
City of Hope National Medical Center – Drug Profiles
5-Fluoro-2-Deoxycytidine + Tetrahydrouridine
Product Description
Mechanism of Action
R&D Progress
Busulfan + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Busulfan + Etoposide + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Busulfan + Fludarabine phosphate
Product Description
Mechanism of Action
R&D Progress
Carmustine + Clophosphamide + Etoposide + Radiation Therapy + Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Carmustine + Cyclophosphamide + Etoposide + Stem Cell Transplantation + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide+Etoposide+yttrium Y 90 ibritumomab tiuxetan+Filgrastim
Product Description
Mechanism of Action
R&D Progress
Cyclosporine + Mycophenolate Mofetil + Methotrexate
Product Description
Mechanism of Action
R&D Progress
Cytarabine + Idarubicin
Product Description
Mechanism of Action
R&D Progress
Cytarabine + Idarubicin + Filgrastim + PBSC + Busulfan + Etoposide + TBI + Aldesleukin
Product Description
Mechanism of Action
R&D Progress
Dasatinib
Product Description
Mechanism of Action
R&D Progress
Doxorubicin Hydrochloride + Ifosfamide + Irinotecan Hydrochloride + Filgrastim + Dexrazoxane Hydrochloride + Conventional surgery + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Amifostine + Cyclophosphamide + Doxorubicin + Paclitaxel + Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Etoposide + Ifosfamide + Paclitaxel + autologous bone marrow transplantation
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cisplatin + Cyclophosphamide + Doxorubicin Hydrochloride + Melphalan + Mesna + Paclitaxel + Tamoxifen Citrate
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Recombinant Interferon Alfa + Busulfan + Cyclophosphamide + Melphalan + Pamidronate Disodium + Thalidomide|Procedure: peripheral blood stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Melphalan
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Ganciclovir
Product Description
Mechanism of Action
R&D Progress
Idarubicin + High Dose Ara-C
Product Description
Mechanism of Action
R&D Progress
Interferon + Thalidomide + Pamidronate
Product Description
Mechanism of Action
R&D Progress
Melphalan + Busulfan + Cyclophosphamide + Filgrastim
Product Description
Mechanism of Action
R&D Progress
Pazopanib Hydrochloride
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Etoposide
Product Description
Mechanism of Action
R&D Progress
Recombinant Interferon Alfa + Semaxanib
Product Description
Mechanism of Action
R&D Progress
Tacrolimus + Methotrexate
Product Description
Mechanism of Action
R&D Progress
Tacrolimus + Sirolimus + Methotrexate
Product Description
Mechanism of Action
R&D Progress
Tamoxifen
Product Description
Mechanism of Action
R&D Progress
Temsirolimus
Product Description
Mechanism of Action
R&D Progress
Aldesleukin + Rituximab + Cytolytic T Cells + Fludarabine Phosphate
Product Description
Mechanism of Action
R&D Progress
CMVpp65-A-0201 Peptide Vaccine
Product Description
Mechanism of Action
R&D Progress
FOLFIRI + Bevacizumab + Yttrium Y 90 DOTA
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Gemcitabine Hydrochloride + Oxaliplatin
Product Description
Mechanism of Action
R&D Progress
Gemcitabine Hydrochloride + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Ixabepilone + Vorinostat
Product Description
Mechanism of Action
R&D Progress
Lenalidomide + Vorinostat
Product Description
Mechanism of Action
R&D Progress
MVAp53 Vaccine
Product Description
Mechanism of Action
R&D Progress
oxaliplatin
Product Description
Mechanism of Action
R&D Progress
Panobinostat + Everolimus
Product Description
Mechanism of Action
R&D Progress
Plerixafor + Filgrastim + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
R115777
Product Description
Mechanism of Action
R&D Progress
Taxotere
Product Description
Mechanism of Action
R&D Progress
Taxotere + Oxaliplatin
Product Description
Mechanism of Action
R&D Progress
Therapeutic allogeneic lymphocytes + Aldesleukin
Product Description
Mechanism of Action
R&D Progress
tipifarnib
Product Description
Mechanism of Action
R&D Progress
Topotecan + Cyclophosphamide + Paclitaxel + Melphalan + Cisplatin + Peripheral blood stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
City of Hope National Medical Center – Pipeline Analysis
City of Hope National Medical Center – Pipeline Products by Therapeutic Class
City of Hope National Medical Center Pipeline Products By Target
City of Hope National Medical Center – Pipeline Products by Route of Administration
City of Hope National Medical Center – Pipeline Products by Molecule Type
City of Hope National Medical Center – Locations And Subsidiaries
Head Office
Financial Deals Landscape
City of Hope National Medical Center Detailed Deal Summary
Acquisition
E.ON UK Acquires Midlands
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS